Longeveron (LGVN) is trading down at $2.51 (-2.71%), as of the latest quote. It operates in the Health Care sector.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $5.63M | $1.31M | $1.22M | $709.0K | $2.39M | $1.20M |
| Growth (year over year) | — | −76.8% | −6.4% | −42.0% | +237.4% | −49.9% |
| Gross profit | $1.83M | $590.0K | $497.0K | $221.0K | $1.88M | $803.0K |
| Gross margin | 32.4% | 45.2% | 40.7% | 31.2% | 78.8% | 67.0% |
| Operating income | −$3.78M | −$17.5M | −$18.0M | −$21.0M | −$16.5M | −$23.3M |
| Operating margin | −67.1% | −1336.6% | −1476.5% | −2966.0% | −690.7% | −1942.2% |
| Net income | −$3.72M | −$17.0M | −$18.8M | −$21.4M | −$16.0M | −$22.7M |
| Net margin | −66.1% | −1305.1% | −1541.3% | −3020.2% | −667.8% | −1893.6% |
| EPS (diluted) | −$23.00 | −$9.00 | −$9.00 | −$10.22 | −$2.62 | −$1.29 |
| Balance sheet | ||||||
| Cash and equivalents | $816.0K | $25.7M | $10.5M | $4.95M | $19.2M | $4.66M |
| Total assets | $9.24M | $42.8M | $27.4M | $12.1M | $25.6M | $10.3M |
| Total liabilities | $7.28M | $5.31M | $6.91M | $5.34M | $3.67M | $4.59M |
| Long-term debt | $311.0K | — | — | — | — | — |
| Shareholders' equity | $1.96M | $37.5M | $20.5M | $6.74M | $21.9M | $5.67M |
| Cash flow | ||||||
| Operating cash flow | −$2.36M | −$9.64M | −$14.0M | −$19.0M | −$13.9M | −$18.6M |
| Capital expenditure | $131.0K | $330.0K | $569.0K | $301.0K | $655.0K | $245.0K |
| Free cash flow | −$2.50M | −$9.97M | −$14.5M | −$19.3M | −$14.5M | −$18.9M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $773.0K | $603.0K | $381.0K | $316.0K | $137.0K | $365.0K | $398.0K | $287.0K |
| Growth (year over year) | +415.3% | — | −30.5% | −32.5% | −82.3% | −39.5% | +4.5% | −9.2% |
| Gross profit | $682.0K | $529.0K | $275.0K | $146.0K | $125.0K | $257.0K | $264.0K | $182.0K |
| Gross margin | 88.2% | 87.7% | 72.2% | 46.2% | 91.2% | 70.4% | 66.3% | 63.4% |
| Operating income | −$4.65M | −$4.28M | −$5.18M | −$5.40M | −$7.31M | −$5.40M | −$4.78M | −$6.17M |
| Operating margin | −601.4% | −710.3% | −1359.8% | −1707.9% | −5335.8% | −1479.2% | −1199.7% | −2150.2% |
| Net income | −$4.42M | −$4.08M | −$5.01M | −$5.03M | −$7.22M | −$5.44M | −$4.74M | −$6.07M |
| Net margin | −571.7% | −677.1% | −1315.2% | −1591.1% | −5270.8% | −1491.5% | −1189.9% | −2116.0% |
| EPS (diluted) | −$0.34 | $1.16 | −$0.34 | −$0.33 | −$0.39 | −$0.23 | −$0.19 | −$0.19 |
| Balance sheet | ||||||||
| Cash and equivalents | $22.8M | $19.2M | $14.3M | $10.3M | $9.24M | $4.66M | $15.8M | $10.1M |
| Total assets | $29.9M | $25.6M | $20.8M | $16.7M | $15.6M | $10.3M | $21.2M | $15.5M |
| Total liabilities | $4.28M | $3.67M | $3.69M | $4.09M | $5.59M | $4.59M | $5.18M | $5.08M |
| Shareholders' equity | $25.6M | $21.9M | $17.2M | $12.7M | $9.97M | $5.67M | $16.0M | $10.4M |
| Cash flow | ||||||||
| Operating cash flow | −$2.84M | −$3.37M | −$4.70M | −$3.60M | −$5.05M | −$5.30M | −$4.37M | −$5.65M |
| Capital expenditure | $430.0K | $13.0K | $27.0K | $161.0K | $57.0K | $0 | $0 | $103.0K |
| Free cash flow | −$3.27M | −$3.39M | −$4.72M | −$3.76M | −$5.11M | −$5.30M | −$4.37M | −$5.76M |
From Longeveron's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Longeveron in our feed yet.